法布里肾病与辅助性肾脏治疗的情况 - Suppr

Fabry nephropathy and the case for adjunctive renal therapy.

作者信息

Wanner Christoph, Breunig Frank

出版信息

J Am Soc Nephrol. 2007 Sep;18(9):2426-8. doi: 10.1681/ASN.2007070783. Epub 2007 Aug 15.

DOI:10.1681/ASN.2007070783

PMID:17699807

Abstract

摘要

相似文献

Fabry nephropathy and the case for adjunctive renal therapy.

J Am Soc Nephrol. 2007 Sep;18(9):2426-8. doi: 10.1681/ASN.2007070783. Epub 2007 Aug 15.

Enzyme replacement therapy and Fabry nephropathy.

Clin J Am Soc Nephrol. 2010 Feb;5(2):371-8. doi: 10.2215/CJN.06900909. Epub 2009 Dec 10.

Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

J Am Soc Nephrol. 2007 Sep;18(9):2609-17. doi: 10.1681/ASN.2006121400. Epub 2007 Jul 26.

Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.

J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471. Epub 2015 Oct 21.

[Fabry nephropathy in a female with superposed IgA glomerulonephritis].

G Ital Nefrol. 2005 Jul-Aug;22(4):385-9.

How should renin-angiotensin system blockade be applied in chronic kidney disease for optimal renal protection?

Chin Med J (Engl). 2007 Feb 5;120(3):243-5.

Agalsidase alfa slows the decline in renal function in patients with Fabry disease.

Am J Nephrol. 2009;29(5):353-61. doi: 10.1159/000168482. Epub 2008 Oct 31.

Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults.

Nat Clin Pract Nephrol. 2008 Jun;4(6):327-36. doi: 10.1038/ncpneph0806. Epub 2008 Apr 22.

New therapeutic strategies with combined renin-angiotensin system inhibitors for pediatric nephropathy.

Pharmacotherapy. 2008 Jan;28(1):125-30. doi: 10.1592/phco.28.1.125.

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.

Hypertens Res. 2008 Jan;31(1):59-67. doi: 10.1291/hypres.31.59.

引用本文的文献

Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review.

Curr Neuropharmacol. 2023;21(3):440-456. doi: 10.2174/1570159X20666220601124117.

Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review.

Cardiovasc Diagn Ther. 2021 Apr;11(2):683-695. doi: 10.21037/cdt-20-743.

Fabry's disease: an example of cardiorenal syndrome type 5.

Heart Fail Rev. 2015 Nov;20(6):689-708. doi: 10.1007/s10741-015-9500-0.

Fabry disease.

Orphanet J Rare Dis. 2010 Nov 22;5:30. doi: 10.1186/1750-1172-5-30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Fabry nephropathy and the case for adjunctive renal therapy.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Fabry nephropathy and the case for adjunctive renal therapy.

作者信息

出版信息

相似文献

引用本文的文献